Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

PURPOSE: The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma. PATIENTS AND METHODS: We conducted a phase I/II clinical study in which patients with recurre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ahmed, Nabil, Brawley, Vita S., Hegde, Meenakshi, Robertson, Catherine, Ghazi, Alexia, Gerken, Claudia, Liu, Enli, Dakhova, Olga, Ashoori, Aidin, Corder, Amanda, Gray, Tara, Wu, Meng-Fen, Liu, Hao, Hicks, John, Rainusso, Nino, Dotti, Gianpietro, Mei, Zhuyong, Grilley, Bambi, Gee, Adrian, Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., Wels, Winfried S., Wang, Lisa L., Anderson, Peter, Gottschalk, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4429176/
https://ncbi.nlm.nih.gov/pubmed/25800760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.0225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados